Nanohale AG (FYB) | WebDisclosure

Switch to English

8302	Sociétés
115146	Mots-clés
55468	Articles
62542	Communiqués

Accueil
Sociétés
Nanohale AG

BRÈVE

publiée le 07/08/2024 à 06:55, il y a 3 mois 15 jours

Formycon Announces Conference Call on 2024 Half-Year Results and Investor Conference Participation

Conference Call Investor Conferences Formycon AG Half-year Results Financial Outlook
COMMUNIQUÉ DE PRESSE

publié le 07/08/2024 à 06:50, il y a 3 mois 15 jours

Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
Formycon schedules conference call on 2024 half-year results and confirms participation in investor conferences. Details on webcast and management presentations

Financial Results Conference Call Investor Conferences Biosimilars Formycon
BRÈVE

publiée le 06/08/2024 à 12:45, il y a 3 mois 15 jours

Formycon AG augmente ses perspectives pour l'exercice 2024

Exercice 2024 Formycon AG EBITDA Ajusté Biosimilaires Fonds De Roulement
BRÈVE

publiée le 06/08/2024 à 12:45, il y a 3 mois 15 jours

Formycon AG Increases 2024 Fiscal Year Outlook

Adjusted EBITDA Working Capital Fiscal Year 2024 Formycon AG Biosimilars
COMMUNIQUÉ DE PRESSE

publié le 06/08/2024 à 12:40, il y a 3 mois 15 jours

EQS-Adhoc: Formycon AG increases its outlook for the 2024 fiscal year
Formycon AG increases its 2024 fiscal year outlook based on positive Lucentis biosimilar performance, adjusting EBITDA and working capital forecasts

Adjusted EBITDA Working Capital Formycon AG 2024 Fiscal Year Lucentis Biosimilar
BRÈVE

publiée le 30/07/2024 à 06:55, il y a 3 mois 23 jours

Formycon commence l'essai clinique de phase III pour le biosimilaire Keytruda® FYB206

Essais Cliniques Formycon Biosimilaire FYB206 Keytruda
BRÈVE

publiée le 30/07/2024 à 06:55, il y a 3 mois 23 jours

Formycon Begins Phase III Clinical Trial for Keytruda® Biosimilar FYB206

Clinical Trials Biosimilar Formycon FYB206 Keytruda
COMMUNIQUÉ DE PRESSE

publié le 30/07/2024 à 06:50, il y a 3 mois 23 jours

Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Formycon AG initiates Phase III clinical trial for FYB206, a Keytruda biosimilar, in NSCLC patients in Eastern Europe and Southeast Asia. Study aims to compare safety and efficacy with Keytruda

Formycon AG NSCLC Phase III Trial FYB206 Keytruda Biosimilar
BRÈVE

publiée le 26/07/2024 à 12:05, il y a 3 mois 26 jours

Formycon et Fresenius Kabi reçoivent un avis positif du CHMP pour FYB202 (Ustekinumab)

Formycon Fresenius Kabi FYB202 Biosimilaire Avis Du CHMP
BRÈVE

publiée le 26/07/2024 à 12:05, il y a 3 mois 26 jours

Formycon and Fresenius Kabi Receive Positive CHMP Opinion for FYB202 (Ustekinumab)

Biosimilar Formycon Fresenius Kabi FYB202 CHMP Opinion

Les Echos

Publié le 21/11/2024 à 06:58, il y a 1 jour 1 heure

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 1 jour 1 heure

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 1 jour 1 heure

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 1 jour 11 heures

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 1 jour 12 heures

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 22/11/2024 à 00:00, il y a 8 heures 7 minutes

Gratomic Announces Company and Operational Update
Publié le 21/11/2024 à 22:05, il y a 10 heures 2 minutes

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Publié le 21/11/2024 à 21:50, il y a 10 heures 17 minutes

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Publié le 21/11/2024 à 20:15, il y a 11 heures 52 minutes

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Publié le 21/11/2024 à 20:10, il y a 11 heures 57 minutes

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

Voir tout ACCESSWIRE

EQS Group

Publié le 22/11/2024 à 07:45, il y a 21 minutes

Preliminary figures for financial year 2023/24 // Significant increase in profitability // Guidance achieved at all levels // Forecast 2024/25
Publié le 22/11/2024 à 07:30, il y a 36 minutes

Pyrum Innovations AG publishes figures for the first nine months of 2024
Publié le 22/11/2024 à 07:30, il y a 37 minutes

Market entry in Belgium: cyan AG is launching a cooperation with Orange Belgium and realizing new growth opportunities
Publié le 22/11/2024 à 07:30, il y a 37 minutes

EQS-Adhoc: All for One Group SE resolves on Share Buyback Programme with a volume of up to EUR 7 million
Publié le 22/11/2024 à 07:23, il y a 43 minutes

EQS-Adhoc: Entering into agreements for the acquisition of a majority stake in OTRS AG by Optimus BidCo AG, an acquisition company of Easyvista SAS, for a purchase price of EUR 17 per share